Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 4
2016 10
2017 6
2018 1
2019 2
2020 4
2021 12
2022 6
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Primary presentation and clinical course of pediatric and adolescent patients with differentiated thyroid carcinoma after radioiodine therapy.
Burgard C, Zacherl MJ, Todica A, Hornung J, Grawe F, Pekrul I, Zimmermann P, Schmid-Tannwald C, Ladurner R, Krenz D, Trupka A, Wagner J, Bartenstein P, Spitzweg C, Wenter V. Burgard C, et al. Among authors: wenter v. Front Oncol. 2023 Oct 2;13:1237472. doi: 10.3389/fonc.2023.1237472. eCollection 2023. Front Oncol. 2023. PMID: 37849815 Free PMC article.
Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor-PET/CT.
Ingenerf M, Rübenthaler J, Wenter V, Zacherl M, Völter F, Winkelmann M, Karim H, Schinner R, Ricke J, Berger F, Schmid-Tannwald C. Ingenerf M, et al. Among authors: wenter v. Front Oncol. 2023 Aug 15;13:1194152. doi: 10.3389/fonc.2023.1194152. eCollection 2023. Front Oncol. 2023. PMID: 37655102 Free PMC article.
Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE.
Eschbach RS, Hofmann M, Späth L, Sheikh GT, Delker A, Lindner S, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Tiling R, Brendel M, Wenter V, Dekorsy FJ, Zacherl MJ, Todica A, Ilhan H, Grawe F, Cyran CC, Unterrainer M, Rübenthaler J, Knösel T, Paul T, Boeck S, Westphalen CB, Spitzweg C, Auernhammer CJ, Bartenstein P, Unterrainer LM, Beyer L. Eschbach RS, et al. Among authors: wenter v. Front Oncol. 2023 Jan 30;13:992316. doi: 10.3389/fonc.2023.992316. eCollection 2023. Front Oncol. 2023. PMID: 36793617 Free PMC article.
Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition.
Resch S, Takayama Fouladgar S, Zacherl M, Sheikh GT, Liubchenko G, Rumiantcev M, Unterrainer LM, Wenter V, Bartenstein P, Ziegler SI, Ilhan H, Beyer L, Böning G, Delker A. Resch S, et al. Among authors: wenter v. EJNMMI Phys. 2023 Feb 9;10(1):11. doi: 10.1186/s40658-023-00529-8. EJNMMI Phys. 2023. PMID: 36757516 Free PMC article.
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging.
Delker A, Schleske M, Liubchenko G, Berg I, Zacherl MJ, Brendel M, Gildehaus FJ, Rumiantcev M, Resch S, Hürkamp K, Wenter V, Unterrainer LM, Bartenstein P, Ziegler SI, Beyer L, Böning G. Delker A, et al. Among authors: wenter v. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1280-1290. doi: 10.1007/s00259-022-06092-1. Epub 2023 Jan 11. Eur J Nucl Med Mol Imaging. 2023. PMID: 36629878 Free PMC article.
Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma.
Li Z, Holzgreve A, Unterrainer LM, Ruf VC, Quach S, Bartos LM, Suchorska B, Niyazi M, Wenter V, Herms J, Bartenstein P, Tonn JC, Unterrainer M, Albert NL, Kaiser L. Li Z, et al. Among authors: wenter v. Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):535-545. doi: 10.1007/s00259-022-05988-2. Epub 2022 Oct 13. Eur J Nucl Med Mol Imaging. 2023. PMID: 36227357 Free PMC article.
Preoperative Imaging with [18F]-Fluorocholine PET/CT in Primary Hyperparathyroidism.
Dekorsy FJ, Beyer L, Spitzweg C, Schmidmaier R, Todica A, Trupka A, Cyran CC, Berger F, Ladurner R, Zimmermann P, Knösel T, Bartenstein P, Lottspeich C, Wenter V. Dekorsy FJ, et al. Among authors: wenter v. J Clin Med. 2022 May 23;11(10):2944. doi: 10.3390/jcm11102944. J Clin Med. 2022. PMID: 35629070 Free PMC article.
Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac-PSMA-I&T.
Unterrainer LM, Beyer L, Zacherl MJ, Gildehaus FJ, Todica A, Kunte SC, Holzgreve A, Sheikh GT, Herlemann A, Casuscelli J, Brendel M, Albert NL, Wenter V, Schmidt-Hegemann NS, Kunz WG, Cyran CC, Ricke J, Stief CG, Bartenstein P, Ilhan H, Unterrainer M. Unterrainer LM, et al. Among authors: wenter v. Biomedicines. 2022 Apr 20;10(5):946. doi: 10.3390/biomedicines10050946. Biomedicines. 2022. PMID: 35625683 Free PMC article.
Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma.
Unterrainer LM, Lindner S, Eismann L, Casuscelli J, Gildehaus FJ, Bui VN, Albert NL, Holzgreve A, Beyer L, Todica A, Brendel M, Cyran CC, Karl A, Stief CG, Ledderose ST, Unterrainer M, Bartenstein P, Wenter V, Kretschmer A. Unterrainer LM, et al. Among authors: wenter v. Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3571-3580. doi: 10.1007/s00259-022-05761-5. Epub 2022 Mar 24. Eur J Nucl Med Mol Imaging. 2022. PMID: 35325283 Free PMC article.
44 results